Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Reunion Neuroscience Inc. - Common Shares
(NQ:
REUN
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EDT, Jul 31, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Reunion Neuroscience Inc. - Common Shares
< Previous
1
2
Next >
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
August 14, 2023
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published
Via
Benzinga
Reunion Neuroscience Completes Take-Private Setup: Delisting & Consideration Details
August 01, 2023
Clinical-stage psychedelics biotech Reunion Neuroscience (NASDAQ: REUN) and MPM BioImpact have completed their announced plan of arrangement for MPM&rsq
Via
Benzinga
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
July 24, 2023
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal...
Via
Benzinga
Terran Biosciences Steps Into 4-OH-DiPT Prodrug Arena With New Patent Application
July 18, 2023
As Reunion Neuroscience (NASDAQ: REUN) and Mindset Pharma (OTCMKTS: MSSTF) continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran Biosciences has also...
Via
Benzinga
Recap: Reunion Neuroscience Q4 Earnings
June 29, 2023
Via
Benzinga
Reunion Neuroscience: Q4 Earnings Insights
June 29, 2023
Via
Benzinga
What's Going On With Reunion Neuroscience Stock Today
June 02, 2023
Via
Benzinga
Reunion Neuroscience On The Brink Of Going Private With Final Court Approval
July 17, 2023
Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution...
Via
Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
World's Largest Psychedelics Conference Boasts 12K Attendees
Via
Benzinga
Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3
June 29, 2023
Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ: REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates. Here's a breakdown of the...
Via
Benzinga
The 7 Most Promising Penny Stocks to Buy in June
June 07, 2023
These top penny stocks for June look to have legitimate catalysts that can certainly send share prices higher.
Via
InvestorPlace
Earnings Preview For Reunion Neuroscience
February 13, 2023
Via
Benzinga
Reunion Neuroscience's Earnings: A Preview
February 13, 2023
Via
Benzinga
Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More
June 06, 2023
Major Investor Commits $30 Million To Psychedelics Funding
Via
Benzinga
Reunion Neuroscience Announces $13.1M Take-Private Transaction With Biotech Investment Firm
June 01, 2023
As of May 31, clinical-stage psychedelics company Reunion Neuroscience Inc.
Via
Benzinga
Nasdaq Surges Over 1%; Dollar General Lowers Annual Guidance
June 01, 2023
U.S. stocks extended gains toward the end of trading, with Nasdaq gaining more than 1% on Thursday. The Dow traded up 0.66% to 33,125.22 while the NASDAQ rose 1.2% to 13,090.62. The S&P 500, also rose,...
Via
Benzinga
US Stocks Turn Higher; ISM Manufacturing PMI Drops In May
June 01, 2023
U.S. stocks turned higher midway through trading, with Nasdaq gaining around 100 points on Thursday. The Dow traded up 0.27% to 32,996.06 while the NASDAQ rose 0.76% to 13,034.08. The S&P 500, also...
Via
Benzinga
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
May 01, 2023
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued
Via
Benzinga
Why Victoria's Secret Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 01, 2023
Gainers Reunion Neuroscience Inc. (NASDAQ: REUN) gained 95% to $1.33 after the company announced a $13.1 million take-private transaction with MPM BioImpact.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
May 01, 2023
Via
Benzinga
Reunion Neuroscience Enters Compliance Period, Struggles To Remain NASDAQ Listed
April 25, 2023
Reunion Neuroscience (NASDAQ: REUN) no longer meets the minimum required $1.00 per-common-share for continued listing on the Nasdaq.
Via
Benzinga
Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
April 19, 2023
Gainers China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) gained 85.2% to $1.25 after the company announced the termination of its previously proposed registered direct offering.
Via
Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
March 20, 2023
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered
Via
Benzinga
Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court
March 14, 2023
Clinical-stage biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) filed a lawsuit against drug discovery business Mindset Pharma Inc. (OTCQB: MSSTF) in the District Court of New Jersey.
Via
Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
February 21, 2023
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and...
Via
Benzinga
Reunion Neuroscience Touts 'Transformative' Quarter, Reaffirms Postpartum Depression Treatment
February 14, 2023
Clinical-stage psychedelics biotech Reunion Neuroscience Inc. (NASDAQ: REUN) shared its unaudited financial results for the third quarter, as of Dec. 31, 2022. Cash and investments totaled $24.3...
Via
Benzinga
'Sea Change': Irwin Naturals, Numinus And Field Trip Discuss Psychedelics At Cantor Webinar
February 03, 2023
Cantor Fitzgerald's Pablo Zuanic hosted a virtual panel discussion about the psychedelics industry with three ketamine therapy providers: Irwin Naturals (OTCMKTS: IWINF)’ CEO Klee Irwin, Field Trip H&W...
Via
Benzinga
Earnings Scheduled For February 14, 2023
February 14, 2023
Companies Reporting Before The Bell • WESCO International (NYSE:WCC) is projected to report quarterly earnings at $3.79 per share on revenue of $5.37 billion.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
January 30, 2023
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday!
Via
InvestorPlace
Could This New Psychedelic Substance Help Treat Postpartum Depression? Researchers Aim To Find Out
January 09, 2023
Psychedelics biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) announced it is undertaking a Phase 1 clinical trial on RE104, which is a novel serotonergic substance that could treat...
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.